FDA approval is a monumental milestone for any emerging pharma or biotech company. However, for first-time sponsors, ringing the bell on approval is just the beginning.
The transition into maintaining an operationally critical, inspection-ready Pharmacovigilance (PV) function is a complex hurdle, and the effort required is frequently underestimated.
Too often, sponsors fall into completely avoidable traps such as delaying launch readiness, underinvesting in robust governance, or maintaining poor operational control.
Break down these common pitfalls and gain actionable strategies to help you build a compliant, scalable PV system from day one and ensure your transition from approval to execution is seamless and audit-ready.
Want to explore these strategies with our experts and ask your most pressing questions? Dive deeper into this matter during our live webinar, Is Your PV Launch Ready?, on June 22nd.
Author
Dr. Narayan Tripathi is a seasoned and performance-driven healthcare professional with over 16 years of experience in Pharmacovigilance (PV). Currently serving as Senior Director of Pharmacovigilance at EVERSANA, he leads a team of over…